TY  - JOUR
AU  - Muñoz-Guardiola, Pau
AU  - Casas, Josefina
AU  - Megías-Roda, Elisabet
AU  - Solé, Sònia
AU  - Perez-Montoyo, Héctor
AU  - Yeste-Velasco, Marc
AU  - Erazo, Tatiana
AU  - Diéguez-Martínez, Nora
AU  - Espinosa-Gil, Sergio
AU  - Muñoz-Pinedo, Cristina
AU  - Yoldi, Guillermo
AU  - Abad, José Luis
AU  - Segura, Miguel 
AU  - Morán, Teresa
AU  - Romeo, Margarita
AU  - Bosch-Barrera, Joaquim
AU  - Oaknin, Ana
AU  - Alfón, José
AU  - Domènech, Carles
AU  - Fabriàs, Gemma
AU  - Velasco Díez, Guillermo
AU  - Lizcano, Jose Miguel
PY  - 2021
DO  - 10.1080/15548627.2020.1761651
SN  - 1554-8627
UR  - https://hdl.handle.net/20.500.14352/101086
T2  - Autophagy
AB  - ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed...
LA  - eng
M2  - 1349
PB  - Taylor & Francis
KW  - Autophagy
KW  - Cancer
KW  - Clinical trial
KW  - Dihydroceramide
KW  - ER stress
KW  - UPR
TI  - The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
TY  - journal article
VL  - 17
ER  -